Kineta (KA) Delisting to OTC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Kineta, Inc Transitioning from Nasdaq to OTC Markets
September 19, 2024 6:23 PM EDTKineta will be trading under the symbol KANT on OTC Pink
Kineta will continue to pursue strategic alternatives as previously announced
TuHURA Biosciences has an exclusivity right and a right of first offer for Kinetas KVA12123 program
The ongoing KVA12123 Phase 1 study is open for new patient enrollment and following those patients previously enrolled.
SEATTLE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer... More
